Barclays Initiates Coverage On CinCor Pharma with Overweight Rating, Announces Price Target of $22
Barclays analyst Leon Wang initiates coverage on CinCor Pharma (NASDAQ:CINC) with a Overweight rating and announces Price Target of $22.
EF Hutton Initiates Coverage On Agenus with Buy Rating, Announces Price Target of $8.3
EF Hutton analyst Michael King initiates coverage on Agenus (NASDAQ:AGEN) with a Buy rating and announces Price Target of $8.3.
HC Wainwright & Co. Initiates Coverage On Gracell Biotechnologies with Buy Rating, Announces Price Target of $6
HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Gracell Biotechnologies (NASDAQ:GRCL) with a Buy rating and announces Price Target of $6.
JMP Securities Initiates Coverage On Full House Resorts with Market Outperform Rating, Announces Price Target of $13
JMP Securities analyst Jordan Bender initiates coverage on Full House Resorts (NASDAQ:FLL) with a Market Outperform rating and announces Price Target of $13.
Needham Initiates Coverage On DigitalOcean Holdings with Buy Rating, Announces Price Target of $36
Needham analyst Mike Cikos initiates coverage on DigitalOcean Holdings (NYSE:DOCN) with a Buy rating and announces Price Target of $36.
BMO Capital Initiates Coverage On Ballard Power Systems with Market Perform Rating, Announces Price Target of $5.5
BMO Capital analyst Ameet Thakkar initiates coverage on Ballard Power Systems (NASDAQ:BLDP) with a Market Perform rating and announces Price Target of $5.5.
UBS Initiates Coverage On Bumble with Neutral Rating, Announces Price Target of $24
UBS analyst Kunal Madhukar initiates coverage on Bumble (NASDAQ:BMBL) with a Neutral rating and announces Price Target of $24.
Piper Sandler Initiates Coverage On JPMorgan Chase with Overweight Rating, Announces Price Target of $150
Piper Sandler analyst Scott Siefers initiates coverage on JPMorgan Chase (NYSE:JPM) with a Overweight rating and announces Price Target of $150.
Bio Rad Has Almost 40% Upside On Revenue Acceleration And Margin Improvement, Analyst Says
RBC Capital Markets initiated coverage on Bio-Rad Laboratories Inc (NYSE:BIO) with an Outperform rating and a $565 price target. The analyst writes…
Ladenburg Thalmann Initiates Coverage On NeuroBo Pharmaceuticals with Buy Rating, Announces Price Target of $6
Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on NeuroBo Pharmaceuticals (NASDAQ:NRBO) with a Buy rating and announces Price Target of $6.